Cheri Franklin
Internal Medicine · Orangeburg, SCNPI 1841259884
Payments from drug & device makers
Across 93 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$287
- Novo Nordisk$148
- Boehringer Ingelheim$137
- AstraZeneca$129
- AbbVie$111
- Lilly USA, LLC$87
- plus $538 from 21 others
What the payments were for
- Food & beverage$1,438100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 18 | $287 |
| Novo Nordisk | 10 | $148 |
| Boehringer Ingelheim | 9 | $137 |
| AstraZeneca | 10 | $129 |
| AbbVie(2 entities) | 5 | $111 |
| Lilly USA, LLC | 7 | $87 |
| Otsuka America Pharmaceutical, Inc. | 2 | $56 |
| Novartis | 3 | $47 |
| Biohaven Pharmaceuticals, Inc. | 2 | $44 |
| GSK | 3 | $43 |
| Merck | 3 | $40 |
| Johnson & Johnson | 2 | $30 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Optinose US, Inc. | 2 | $27 |
| Eisai Inc. | 2 | $26 |
| Astellas Pharma US Inc | 1 | $24 |
| Amarin Pharma, Inc. | 2 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Medtronic | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Pfizer | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Zyla Life Sciences, Inc. | 1 | $11 |
How this compares
$1,438 in reported general payments places this provider in the 70th percentile of 1,498 internal medicine providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 131 | $59,346 |
| DapagliflozinDapagliflozin Propanediol | 104 | $44,777 |
| EntrestoSacubitril/Valsartan | 61 | $32,707 |
| ProcritEpoetin Alfa | 13 | $28,267 |
| JanuviaSitagliptin Phosphate | 54 | $24,527 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 61 | $19,448 |
| OzempicSemaglutide | 14 | $14,368 |
| Mirabegron ErMirabegron | 29 | $9,289 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $8,376 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 48 | $8,233 |
| GemtesaVibegron | 13 | $5,660 |
| XareltoRivaroxaban | 26 | $4,990 |
| Atorvastatin Calcium | 358 | $3,288 |
| Levetiracetam | 77 | $3,115 |
| Potassium Chloride | 128 | $3,019 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $12 | $59,346131 claims |
| Johnson & JohnsonProcrit, Xarelto | $30 | $33,25739 claims |
| NovartisEntresto | $47 | $32,70761 claims |
| MerckJanuvia | $40 | $24,52754 claims |
| Novo NordiskOzempic | $148 | $14,36814 claims |
| GSKTrelegy Ellipta | $43 | $8,37612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Orangeburg
- Rubin PatelOrangeburg$183K
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl SofleyAnderson$673K
- Carl MitchellColumbia$564K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.